CVRX - CVRx: Barostim Story Looks Well Priced In Overvalued At Just 5x Sales

• CVRx's Barostim is a long-term compounder that presents with interesting economics.
• Clinical data is robust for the device and it continues to benefit from regulatory tailwinds.
• News around the device has been well priced into the stock, however, as investors price in growing systematic risks and unwind the growth trade.
• Investors have de-risked away from top-line growth toward bottom-line fundamentals, hurting CVRX's share price.
• Here are the relevant parts to the CVRX investment debate.

For further details see: